EVIDENCE PROFILE / PUBLISHED
DSIP / Emideltide
DSIP is a nonapeptide historically called delta sleep-inducing peptide; endogenous identity and physiological role have been debated. A 16-person double-blind insomnia study found weak objective signals that could partly reflect placebo change and concluded major therapeutic benefit was unlikely.
Evidence at a glance
- Human
- LimitedOne small double-blind study in 16 people.
- Animal/cell
- Not rated
- Approved medicine
- None foundScope: the Canadian and U.S. sources reviewed.
Summarises how much research the profile's sources report, and of what kind. It is not a verdict on the compound or on any catalogue material.
PREPPY BOY ASKS
“A familiar name can hide a different molecule, fragment, formulation, or evidence story.”
The catalogue name is a starting point, not proof of formulation or identity. Older work examined sleep architecture, stress-axis biomarkers, and neuroendocrine responses.
Identity
DSIP is a nonapeptide historically called delta sleep-inducing peptide; endogenous identity and physiological role have been debated.
Biological mechanism or research interest
Older work examined sleep architecture, stress-axis biomarkers, and neuroendocrine responses.
Verified approved human uses
No approved human use was verified in the reviewed Canadian or U.S. sources.
Investigational human evidence
A 16-person double-blind insomnia study found weak objective signals that could partly reflect placebo change and concluded major therapeutic benefit was unlikely.
Popular claims versus demonstrated findings
Sleep restoration, stress reduction, pain control, and endocrine normalization are not established by the small, old studies.
Human versus animal or cell evidence
Animal and biomarker research does not resolve whether the peptide has a clinically useful sleep effect.
Limitations and known risks
FDA reports inadequate proposed-route safety information and potential peptide immunogenicity or impurity concerns; modern pharmacokinetic and long-term safety data are sparse.
